Cancer Chemotherapy and Pharmacology

, Volume 36, Issue 4, pp 279–282 | Cite as

Taxol encapsulation in poly(ɛ-caprolactone) microspheres

  • Stephen K. Dordunoo
  • John K. Jackson
  • Larry A. Arsenault
  • Ann Marie C. Oktaba
  • William L. Hunter
  • Helen M. Burt
Original Article Taxol, Microspheres Antiangiogenesis

Abstract

Poly(ɛ-caprolactone) (PCL) microspheres containing taxol were prepared by the solvent evaporation method and tested for angiogenesis inhibition using the chick chorioallantoic membrane (CAM) model. Very high encapsulation efficiencies (95%) for taxol in PCL microspheres were obtained. In vitro release studies showed about 25% of the loaded drug was released in 6 weeks from microspheres containing 5% taxol. Studies with the CAM showed that taxol released from the microspheres induced vascular regression and inhibited angiogenesis.

Key words

Taxol Microspheres Antiangiogenesis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bodmeier R, McGinity JW (1987) The preparation and evaluation of drug containing poly(D,L-lactide) microspheres formed by the solvent evaporation method. Pharm Res 4: 465Google Scholar
  2. 2.
    Engelberg I, Kohn J (1991) Physico-mechanical properties of degradable polymers used in medical applications. Biomaterials 12: 292Google Scholar
  3. 3.
    Ichihara T, Sakamoto K, Mori K, Akagi M (1989) Transcatheter arterial chemoembolization therapy for hepatocellular carcinoma using polylactic acid microspheres containing aclarubicin hydrochloride. Cancer Res 49: 4357Google Scholar
  4. 4.
    Izumikawa S, Yoshioka S, Aso Y, Takeda Y (1991) Preparation of poly(l-lactide) microspheres of different crystalline morphology and effect of crystalline morphology on drug release rate. J Controlled Release 15: 133Google Scholar
  5. 5.
    Kamei S, Okada H, Inoue Y, Yoshika T, Ogawa Y, Toguchi H (1993) Anti-tumor effects of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution. J Pharmacol Exp Ther 264: 469Google Scholar
  6. 6.
    Lopes NM, Adams EG, Pitts TW, Bhuyan BK (1993) Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32: 235Google Scholar
  7. 7.
    Manfredi JJ, Parnes J, Horwitz SB (1982) Taxol binds to cellular microtubules. J Cell Biol 94: 688Google Scholar
  8. 8.
    Nakamura H, Mitani T, Murakami T, Toru H, Tsuda K, Nakanishi K, Ishida T, Tomoda K, Hori S, Kozuka T, Monden M, Kuroda C (1994) Five year survival after transcatheter chemoembolization for bepatocellular carcinoma. Cancer Chemother Pharmacol [Suppl] 33: S89Google Scholar
  9. 9.
    Okamoto Y, Konno A, Togawa K, Kato T, Tamakawa Y, Amaro Y (1986) Arterial chemoembolization with cisplatin microcapsules. Br J Cancer 53: 369Google Scholar
  10. 10.
    Reference deletedGoogle Scholar
  11. 11.
    Pitt CG (1990) Poly ɛ-caprolactone and its copolymers. In: Chasin M, Langer R (eds) Biodegradable polymers as delivery systems. Marcel Dekker, New York, p 71.Google Scholar
  12. 12.
    Pitt CG, Hendren RW, Schindler A, Woodward SC (1984) The enzymatic surface erosion of aliphatic polyesters. J Controlled Release 1: 3Google Scholar
  13. 13.
    Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247Google Scholar
  14. 14.
    Sato T, Kanke M, Schroeder HG, DeLuca PP (1988) Porous degradable microspheres for controlled drug delivery. I. Assessment of processing conditions and solvent removal techniques. Pharm Res 5: 21Google Scholar
  15. 15.
    Sefton MV, Brown LR, Langer RS (1984) Ethylene-vinyl acetate copolymer microspheres for controlled release of macromolecules. J Pharm Sci 71: 1859Google Scholar
  16. 16.
    Spenlehauer G, Vert M, Benoit J-P, Chabot F, Veillard M (1988) Biodegradable cisplatin microspheres prepared by the solvent evaporation method: Morphology and release characteristics. J Controlled Release 7: 217Google Scholar
  17. 17.
    Stearns ME, Wang M (1992) Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer es 52: 3776Google Scholar
  18. 18.
    Stracke ML, Soroush M, Liotta CA, Schiffman E (1993) Cytoskeletal agents inhibit motility and adherence of human tumor cells. Kidney Int 43: 151Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • Stephen K. Dordunoo
    • 1
  • John K. Jackson
    • 1
  • Larry A. Arsenault
    • 2
  • Ann Marie C. Oktaba
    • 2
  • William L. Hunter
    • 3
  • Helen M. Burt
    • 1
  1. 1.Faculty of Pharmaceutical SciencesUniversity of British ColumbiaVancouverCanada
  2. 2.Department of PathologyMcMaster UniversityHamiltonCanada
  3. 3.Angiogenesis Technologies Inc.VancouverCanada

Personalised recommendations